Irbesartan Viatris

Irbesartan, the active ingredient in Irbesartan Viatris, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is prescribed to lower blood pressure in hypertension and to slow the progression of renal disease in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to control blood pressure and protect kidney function. - Hypertension: reduces systolic and diastolic pressure, decreasing cardiovascular risk. - Diabetic nephropathy: slows the decline of renal function in adults with type 2 diabetes and proteinuria.

Irbesartan may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Upper respiratory tract infection - Mild hyperkalemia

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hyperkalemia - Acute renal failure or worsening renal function - Symptomatic hypotension

Before initiating Irbesartan, several safety considerations are recommended. - Blood pressure monitoring: check baseline and periodic readings. - Renal function assessment: evaluate serum creatinine and eGFR. - Serum potassium: monitor for hyperkalemia, especially with potassium‑sparing agents. - Hepatic impairment: use caution and consider dose adjustment. - Pregnancy: avoid use due to potential fetal toxicity. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Irbesartan can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment and hyperkalemia. - Concurrent ACE inhibitor or other ARB: heightened risk of hypotension and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause severe hyperkalemia. - NSAIDs (e.g., ibuprofen): can reduce renal perfusion and blunt antihypertensive effect.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium levels, risking toxicity. - Thiazide diuretics: can enhance antihypertensive effect, monitor blood pressure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise Irbesartan plasma concentrations. - CYP3A4 inducers (e.g., rifampin): may lower drug exposure, reducing efficacy.